Stem cell therapy: A novel approach for myocardial infarction

Parizadeh, Seyed Mostafa; Jafarzadeh‐Esfehani, Reza; Ghandehari, Maryam; Parizadeh, Mohammad Reza; Ferns, Gordon A.; Rezayi, Majid; Hassanian, Seyed Mahdi

doi:10.1002/jcp.28381

Cited by 33 publications

(22 citation statements)

References 69 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Irreversible death of cardiomyocytes and scar formation due to prolonged ischemia of myocardium in consequence lead to adverse remodeling of the left ventricle. Contractile dysfunction of the left ventricle and cardiac arrhythmias represent common results of remodeling and most serious complications in patients with heart failure [27]. Strategies to prevent of remodeling, consecutive heart failure, and sudden death are urgently required.…”

Section: Discussionmentioning

confidence: 99%

Novel Evidence of the Increase in Angiogenic Factor Plasma Levels after Lineage-Negative Stem/Progenitor Cell Intracoronary Infusion in Patients with Acute Myocardial Infarction

Baumert

Przybycień

Paczkowska

et al. 2019

IJMS

View full text Add to dashboard Cite

Cell therapy raises hope to reduce the harmful effects of acute myocardial ischemia. Stem and progenitor cells (SPCs) may be a valuable source of trophic factors. In this study, we assessed the plasma levels of selected trophic factors in patients undergoing application of autologous bone marrow (BM)-derived, lineage-negative (Lin−) stem/progenitor cells into the coronary artery in the acute phase of myocardial infarction. The study group consisted of 15 patients with acute myocardial infarction (AMI) who underwent percutaneous revascularization and, afterwards, Lin− stem/progenitor cell administration into the infarct-related artery. The control group consisted of 19 patients. BM Lin− cells were isolated using immunomagnetic methods. Peripheral blood was collected on day 0, 2, 4, and 7 and after the first and third month to assess the concentration of selected trophic factors using multiplex fluorescent bead-based immunoassays. We found in the Lin− group that several angiogenic trophic factors (vascular endothelial growth factor, Angiopoietin-1, basic fibroblast growth factor, platelet-derived growth factor-aa) plasma level significantly increased to the 4th day after myocardial infarction. In parallel, we noticed a tendency where the plasma levels of the brain-derived neurotrophic factor were increased in the Lin– group. The obtained results suggest that the administered SPCs may be a valuable source of angiogenic trophic factors for damaged myocardium, although this observation requires further in-depth studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Evidence of the Increase in Angiogenic Factor Plasma Levels after Lineage-Negative Stem/Progenitor Cell Intracoronary Infusion in Patients with Acute Myocardial Infarction

Baumert

Przybycień

Paczkowska

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The clinical use and efficiency of autologous stem cells is currently limited because most MI patients are elderly and the stem cells obtained from these patients are mostly aged [ 84 , 85 ]. The application of the strategy described in this section can be utilized to rejuvenate aged stem cells.…”

Section: Genetically Modified Stem Cell For MI Treatmentmentioning

confidence: 99%

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment

Raziyeva

Smagulova

Kim

et al. 2020

IJMS

View full text Add to dashboard Cite

Ischemic heart disease and myocardial infarction remain leading causes of mortality worldwide. Existing myocardial infarction treatments are incapable of fully repairing and regenerating the infarcted myocardium. Stem cell transplantation therapy has demonstrated promising results in improving heart function following myocardial infarction. However, poor cell survival and low engraftment at the harsh and hostile environment at the site of infarction limit the regeneration potential of stem cells. Preconditioning with various physical and chemical factors, as well as genetic modification and cellular reprogramming, are strategies that could potentially optimize stem cell transplantation therapy for clinical application. In this review, we discuss the most up-to-date findings related to utilizing preconditioned stem cells for myocardial infarction treatment, focusing mainly on preconditioning with hypoxia, growth factors, drugs, and biological agents. Furthermore, genetic manipulations on stem cells, such as the overexpression of specific proteins, regulation of microRNAs, and cellular reprogramming to improve their efficiency in myocardial infarction treatment, are discussed as well.

show abstract

“…Therefore, they have been considered to be promising tools for cardiac tissue regeneration [ 20 , 77 , 78 ]. Many reports have demonstrated the therapeutic potential of various stem cell types, such as bone marrow-derived stem cells (BMSCs), ADSCs, cardiac-derived stem cells/cardiac progenitor cells (CPCs), and others, on myocardial tissue regeneration [ 79 , 80 , 81 , 82 , 83 ]. Moreover, stem cells have shown their therapeutic efficiency in several clinical trials [ 84 ].…”

Section: Biomaterials Loaded With Stem Cells For Cardiac Tissue Rementioning

confidence: 99%

Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration

Smagul

Kim

Smagulova

et al. 2020

IJMS

View full text Add to dashboard Cite

Myocardial infarction causes cardiac tissue damage and the release of damage-associated molecular patterns leads to activation of the immune system, production of inflammatory mediators, and migration of various cells to the site of infarction. This complex response further aggravates tissue damage by generating oxidative stress, but it eventually heals the infarction site with the formation of fibrotic tissue and left ventricle remodeling. However, the limited self-renewal capability of cardiomyocytes cannot support sufficient cardiac tissue regeneration after extensive myocardial injury, thus, leading to an irreversible decline in heart function. Approaches to improve cardiac tissue regeneration include transplantation of stem cells and delivery of inflammation modulatory and wound healing factors. Nevertheless, the harsh environment at the site of infarction, which consists of, but is not limited to, oxidative stress, hypoxia, and deficiency of nutrients, is detrimental to stem cell survival and the bioactivity of the delivered factors. The use of biomaterials represents a unique and innovative approach for protecting the loaded factors from degradation, decreasing side effects by reducing the used dosage, and increasing the retention and survival rate of the loaded cells. Biomaterials with loaded stem cells and immunomodulating and tissue-regenerating factors can be used to ameliorate inflammation, improve angiogenesis, reduce fibrosis, and generate functional cardiac tissue. In this review, we discuss recent findings in the utilization of biomaterials to enhance cytokine/growth factor and stem cell therapy for cardiac tissue regeneration in small animals with myocardial infarction.

show abstract

Stem cell therapy: A novel approach for myocardial infarction

Cited by 33 publications

References 69 publications

Novel Evidence of the Increase in Angiogenic Factor Plasma Levels after Lineage-Negative Stem/Progenitor Cell Intracoronary Infusion in Patients with Acute Myocardial Infarction

Novel Evidence of the Increase in Angiogenic Factor Plasma Levels after Lineage-Negative Stem/Progenitor Cell Intracoronary Infusion in Patients with Acute Myocardial Infarction

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment

Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration

Contact Info

Product

Resources

About